Gene Editing Market Size By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENs), By End-user (Biotech and Pharma Companies, Contract Research Organizations (CROs), Research Institutes), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Published Date: Sep 2020  |  Report ID: GMI810  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 141   |   Base Year: 2019

Summary Table of Contents Industry Coverage Methodology

Industry trends

Gene Editing Market size was valued at over USD 3.8 billion in 2019 and is expected to grow at a CAGR of 14.9% from 2020 to 2026. Increasing advancements in gene editing technologies are anticipated to boost the market growth. Growing awareness regarding availability of genetically modified crops and animals will have positive impact on the overall market expansion.

Gene Editing Market Overview

Get more details on this report - Request Free Sample PDF

Growing utilization of synthetic genes in incorporating newer biosynthetic pathway in microorganisms to manufacture biologics will escalate the gene editing market share over the forecast period. Scientific communities are considering gene editing tools such as CRISPR to potentially disrupt the SARS-CoV-2 genome, the virus that causes COVID-19. This is poised to create growth opportunities for the businesses to invest in the market.

Rising funding for genetic research will augment the gene editing market progression

Increased funding for genetic research in developed regions including North America will propel the industry expansion over the forecast period. The U.S. government funds various research programs that facilitates the process of drug discovery for several rare genetic diseases. The National Institutes of Health (NIH), a primary agency of the U.S. government is responsible for research in biomedical and genetics and grants billions of dollars in funding. For instance, about USD 1.6 million of funding from NIH allowed research team of Arizona State University and Baylor College of Medicine to evaluate advances in human genome editing. This funding also assisted in developing recommendations regarding governing of technologies and its future prospects. Research activities for drug discovery increase the preference for gene editing techniques and thus, extensive usage of gene editing techniques will stimulate the industry progression. Also, recently developed therapies and drugs used in treatment of genetic diseases have reduced the mortality rates that will influence the market revenue in the coming years.

Growing demand for CRISPR/Cas9 technology will favour the gene editing market value

The CRISPR/Cas9 segment is estimated to register growth of more than 15% by 2026. Rising demand for CRISPR/Cas9 in altering the genome of organisms to develop commercially feasible products will accelerate the industry revenue. Also, CRISPR technology is easy to use, simple, and inexpensive unlike the other gene editing techniques such as TALENs, thereby, increasing its adoption rate. Key market players such as Thermo Fisher Scientific, Takara Bio, Caribou Biosciences are focusing on R&D activities for adding innovations in the CRISPR/Cas9 technology that has raised preference in research processes escalating the market growth.

Increasing application of cell line engineering will escalate the overall market expansion

Gene Editing Market Size

Get more details on this report - Request Free Sample PDF

The gene editing market for cell line engineering segment accounted for USD 1.5 billion in 2019. Cell-line engineering technology has wide applications in stem cell research, particularly for induced pluripotent stem cells (iPSCs) that helps in genetically modifying the stem cell resulting in rapid growth of iPSCs lines. Recent advances in gene editing techniques including CRISPR/Cas, TALENs and Zinc Finger Nucleases (ZFNs) have made cell engineering easy and cheaper, thereby fuelling its demand and escalating the segment growth during the forecast timeline.

Rising focus on developing novel gene editing technologies will offer significant growth opportunities for the market

The biotech and pharma companies segment held around 46% of the gene editing market share in 2019 led by the increasing focus of biotech companies on developing advanced gene editing technologies. For instance, Bio-Rad Laboratories aims to create genome editing tools pipeline by launching several gene editing tools including digital droplet PCR (ddPCR). Technological advancements in gene editing enable market leaders to develop advanced technologies that are efficient enough in treatment of a specific genetic disease as compared to the conventional therapies, driving the industry value.

Increasing acceptance rate of gene editing techniques in North America region will spur the market progression

North America Gene Editing Market

Get more details on this report - Request Free Sample PDF

North America gene editing market captured 37% of revenue share in 2019. Rising prevalence of rare diseases in the U.S. and Canada has stimulated the demand for gene editing techniques that are used in developing drugs. As per the Rare Genomics Institute, 1 in 10 people suffer from rare disease across the U.S. Also, developed countries such as the U.S. has significant adoption rate of gene editing technologies such as CRISPR-Cas9, TALENs and ZFNs due to increase in research activities and affordability of high-end technologies fostering the market revenue.

Strategic initiatives undertaken by leading market players have helped them develop advanced product portfolio

Some of the leading companies operating in the gene editing market include Thermo Fisher Scientific, Integrated DNA Technologies, Agilent Technologies, EMD Millipore (Merck KGAa), Takara Bio, Horizon Discovery, Origene Technologies, Sangamo Therapeutics, Caribou Biosciences and others. These market participants are undertaking several organic and inorganic growth strategies to garner higher revenue in the market.

Recent Gene Editing Market Developments:

  • In May 2020, Caribou Science entered into commercial and clinical license agreement with MaxCyte. The agreement was aimed to gain exclusive rights to use MaxCyte’s flow electroporation technology as well as ExPERT platform. This is slated to advance Caribou’s gene-edited allogenic T cell therapy programs and expand their corporate relations in the market.
  • In June 2019, Allele Biotechnology and Alpine BioTherapeutics Corporation announced an agreement for developing induced pluripotent stem cells for treatment of retinal diseases. This strategy assisted the company in developing advanced product portfolio.

The gene editing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

Market, By Application, 2015-2026 (USD Million)

  • Cell line engineering
  • Animal genetic engineering
  • Plant genetic engineering
  • Others

Market, By Technology, 2015-2026 (USD Million)

  • CRISPR/Cas9
  • Zinc Finger Nucleases (ZFNs)
  • TALENs
  • Others

Market, By End-user, 2015-2026 (USD Million)

  • Biotech and pharma companies
  • Contract research organizations (CROs)
  • Research institutes

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Poland
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE


Frequently Asked Questions (FAQ) :

In 2019, the global market size for gene editing was worth USD 3.8 billion and may register 14.9% CAGR between 2020 and 2026.
CRISPR/Cas9 segment will observe 15% CAGR through 2026, as the technology is widely used for altering the genome of organisms to develop commercially feasible products.
North America held 37% of the industry share in 2019 and may exhibit commendable traction due to increasing prevalence of rare diseases in the U.S. and Canada.
The cell line engineering segment was worth USD 1.5 billion in 2019. The application segment will exhibit immense growth owing to rising cell engineering usage in stem cell research.
The biotech and pharma companies segment led the global industry with 46% share in 2019 and will depict appreciable growth, owing to rising focus of biotech firms to develop advanced gene editing technologies.

Premium Report Details

  • Published Date: Sep 2020
  • Pages: 141
  • Tables: 103
  • Charts / Figures: 14
  • Companies covered: 22
  • Countries covered: 20

Get a report that explains COVID-19 impact on this market

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X